As of today (2024-05-01), Lonza Group's share price is $55.33.
Lonza Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.43. Hence, Lonza Group's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Lonza Group's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 13 years, Lonza Group's highest Price-to-Free-Cash-Flow Ratio was 370.20. The lowest was 8.56. And the median was 35.65.
LZAGY's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 26.13 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 13 years, Lonza Group's highest 3-Year average Free Cash Flow per Share Growth Rate was 64.40% per year. The lowest was -29.20% per year. And the median was 5.60% per year.
Lonza Group Price-to-Free-Cash-Flow Historical Data
The historical data trend for Lonza Group's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lonza Group's Price-to-Free-Cash-Flow
For the Diagnostics & Research subindustry, Lonza Group's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Lonza Group's Price-to-Free-Cash-Flow falls into.
Lonza Group Price-to-Free-Cash-Flow Calculation
Lonza Group's Price-to-Free-Cash-Flow ratio for today is calculated as
Lonza Group's Share Price of today is $55.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lonza Group (OTCPK:LZAGY) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Lonza Group Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Lonza Group's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LZAGY has been successfully added to your 